🚨 Your cardiologist targets an LDL below 70 and calls it good control. A new randomized trial just proved that number is too high. Ez-PAVE randomized 3,048 heart attack survivors to a target below 55 versus below 70, and the lower target cut nonfatal MI by 54%. "But the data says otherwise." And no, this is not another drug trial pretending to answer a target question. I am a cardiologist. I have hundreds of patients on high-intensity statins, ezetimibe, and PCSK9 inhibitors. I have spent years watching patients get told their LDL of 68 is "controlled." Ez-PAVE proves that framing is wrong. 🩺 Here is what the science actually says. For years we had PROVE-IT, TNT, IMPROVE-IT, and FOURIER. Great trials. Wrong question. They tested drugs added to other drugs. None of them randomized patients to an actual LDL target. Ez-PAVE did. 💓 EZ-PAVE (statin, ezetimibe, PCSK9 inhibitor combinations): 3,048 high-risk ASCVD patients in South Korea, randomized to below-55 versus below-70 mg/dL targets, followed a median of 3.0 years. 🔬 The numbers: Median achieved LDL: 56 mg/dL versus 66 mg/dL. Primary endpoint: 6.6% versus 9.7%. HR 0.67, 95% CI 0.52 to 0.86, P=0.002. 33% relative risk reduction. 3.1 percentage point absolute risk reduction. Nonfatal MI: 1.7% versus 8%. A 54% relative reduction. That matters because a 10 mg/dL difference in achieved LDL, nothing more, produced that separation. ⚠️ The safety question everyone asks: New-onset diabetes was lower in the intensive group, 6% versus 16.1%. Kidney function was better in the intensive group, not worse. Creatinine elevation 2% versus 2.7%, P=0.004. No increase in muscle symptoms, cancer, or liver enzymes. Going lower did not cost these patients anything. It protected them. 🔸 One subgroup showed a numerically worse HR of 1.22 in women. The confidence interval crossed 1.0, 0.66 to 2.28, and only 638 women were enrolled. This trial was not powered for sex-specific analysis. That is a statistical artifact, not a safety signal. Do not let anyone tell you otherwise. ❌ Only 60.8% of the intensive group even reached below-55, in a research setting with motivated investigators watching every visit. ❌ In real-world practice, fewer than 25% of eligible patients reach below-55. Fewer than 10% are on ezetimibe. About 1% are on a PCSK9 inhibitor. The gap between what works and what we actually do is enormous. ❤️ Bottom line: An LDL of 70 is not a finish line. It is a compromise we settled for before we had the trial to prove we could do better. This is one randomized trial of 3,048 patients, but it directly answers the target question that four prior landmark trials never asked. Get your LDL checked. If you have known heart disease and your number is above 55, ask your doctor about escalating therapy. Statin. Ezetimibe. PCSK9 inhibitor if needed. A patient who pushes LDL from 68 to 56 mg/dL can meaningfully lower their MI risk within 3 years. That is the difference between a second heart attack and a normal life. The question is no longer whether lower is better. The question is why your LDL still is not below 55. #Cardiology #HeartDisease #HeartHealth #CardiovascularHealth #LDL #Statins #PCSK9 #ApoB #PreventiveCardiology #LifestyleMedicine